Wednesday, December 11th, 2024: Day TwoWednesday, 11 December 2024 - ET (Eastern Time, GMT-05:00)

• Gain insights on the latest trends and innovations shaping the pharamcy sector and the cost of goods
• Understand the challenges currently faced when launching a new product in retail including reimbursement issues and competition from generics
• Understand the Direct-to-Purchase/Direct-to-Patient Model, including bypassing the PBM and the GPO

• Understand the distinct challenges with limited distribution drugs
• Discuss instances where brand name manufacturers may increase prices after LOE to recoup losses or maximize profits

In today's data-driven landscape, making informed decisions hinges on high-quality, accessible data. This session cuts through the jargon and equips you with actionable strategies to unlock the power of your data. Learn how to demystify data concepts and master data management practices to gain a competitive edge.

Hear from top executives from healthcare stakeholders on on how their organizations are taking action on initiatives to:

• Improve patient affordability
• Promote health equity
• Shift towards value
• Protect and support innovation

Explore effective strategies for competitive product positioning and payer engagement in the pharmaceutical industry. Delve into payer positioning strategies, formulary management, brand performance management and benefit design implications. Learn how to define clear objectives and manage challenges such as loss of exclusivity to optimize product positioning and reimbursement outcomes.

As the roles between trade and channel, patient services and market access becomes more and more intertwined, hear directly from Ultragenyx on their strategies for ensuring cross functional collaboration and success for their programs.

• Learn how to leverage provider and patient journey insights to improve dialogue and understanding between health systems and pharmaceutical companies, ensuring alignment and collaborative success in new medication launches
• Discover innovative methods to identify and dismantle traditional barriers that impede effective partnerships, fostering a culture of openness and cooperation that accelerates the adoption of new medical innovations
• Gain insights into creative strategies and unconventional approaches that can redefine how health systems and pharma collaborate, leading to more effective and efficient launch processes and better patient outcomes

The life science landscape is rapidly evolving with the increasing adoption of generics and biosimilars. This session equips you with actionable strategies to navigate this competitive environment and achieve sustainable growth.

• Delve into the current state of generics and biosimilars adoption, highlighting key trends and market segments with high growth potential
• Learn how to effectively position products against competitors, navigate payer negotiations and secure favorable reimbursement decision
• Discuss how health systems are approaching generics and biosimilars and how to tailor approaches to meet evolving needs and priorities
• Gain insights into emerging trends and technologies that will shape the future of generics and biosimilars, allowing you to stay ahead of the curve

• Explore how to target underexplored markets, utilizing payer dynamics to open new doors in health system partnerships
• Gain insights from the strategies and challenges of working in the “Grey Space”, where innovation and collaboration converge, enabling us to navigate uncertainty and uncover shared solutions
• Gain real-world examples on how to transform partnerships and redefine your organization’s market position

• As cell and gene therapies revolutionize patient care, understand the challenges for stakeholders in implementing breakthrough treatments
• Dive into the intricacies of channel strategies specific to cell and gene therapy procurement models, particularly within hospitals and health systems
• Gain insights into the evolving landscape of these advanced therapies, addressing the procurement hurdles, cost considerations, and supply chain implications